Kevin Kaster, J.D.
Mr. Kaster has over 25 years of experience in both smaller biotechnology firms and large pharmaceutical companies. He has an impressive track record of developing effective patent and licensing strategies for important technologies and drug products. Mr. Kaster was formerly the VP Intellectual Properties at Kosan Biosciences, which had geldanamycin and epothilone anti-cancer agents in its pipeline and was acquired by Bristol-Myers Squibb in 2008. Prior to Kosan, he was the VP of Intellectual Property at Geron Corporation. Geron owns rights in telomerase and human embryonic stem cell technologies. Prior to Geron, he was Director of Intellectual Property at Affymax and a Senior Patent Attorney at Cetus Corporation. Mr. Kaster began his career at Eli Lilly and Company, first as a research scientist and then as a patent technician. He received his law degree from Indiana University School of Law - Indianapolis and his Bachelor of Science degree magna cum laude from Vanderbilt University in Chemistry.